Menu Search
Equities

Piramal Pharma Ltd

PPLPHARMA:NSI

Piramal Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)281.55
  • Today's Change-11.25 / -3.84%
  • Shares traded6.42m
  • 1 Year change+138.70%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 10:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 5 analysts offering 12 month price targets for Piramal Pharma Ltd have a median target of 275.00, with a high estimate of 310.00 and a low estimate of 260.00. The median estimate represents a -1.79% decrease from the last price of 280.00.
High10.7%310.00
Med-1.8%275.00
Low-7.1%260.00

Dividends

In 2024, Piramal Pharma Ltd reported a dividend of 0.11 INR. The 2 analysts covering the company expect dividends of 0.35 INR for the upcoming fiscal year, an increase of 218.18%.
Div growth (TTM)--
More ▼

Earnings history & estimates in INR

On May 10, 2024, earnings of 1.00 per share.
The next earnings announcement is expected on May 19, 2025.
Average growth rate+472.35%
Piramal Pharma Ltd reported annual 2024 earnings of 0.63 per share on May 10, 2024.
More ▼

Revenue history & estimates in INR

Piramal Pharma Ltd had 2nd quarter 2025 revenues of 22.42bn. This bettered the 21.95bn consensus of the 2 analysts covering the company. This was 28.18% above the prior year's 2nd quarter results.
Average growth rate+6.03%
Piramal Pharma Ltd had revenues for the full year 2024 of 81.71bn. This was 11.83% above the prior year's results.
Average growth rate+11.83%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.